<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02898714</url>
  </required_header>
  <id_info>
    <org_study_id>FUTURE-59342</org_study_id>
    <nct_id>NCT02898714</nct_id>
  </id_info>
  <brief_title>Flash Glucose Monitoring Study for Diabetes</brief_title>
  <acronym>FUTURE</acronym>
  <official_title>The Impact of Flash Glucose Monitoring on Clinical Outcome Parameters in Diabetes Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      On the first of July 2016, the Freestyle Libre Flash Glucose Monitor (FGM) will be reimbursed
      in Belgium by means of a new diabetes reimbursement program for adults. For children, the
      Freestyle Libre FGM is also reimbursed by means of a new reimbursement program from the first
      of August 2016 onwards. Making this the only way to receive the device in Belgium. To
      understand the impact of this new FGM on diabetes patients in UZ Leuven, OLVZ Aalst, and UZ
      Antwerp, we want to study the use of the device by our patients by means of an observational
      study where patients complete questionnaires at regular time points in the first year of
      usage and after 24 months Clinical data will be gathered during the routine clinical visits
      as part of the reimbursement program.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">June 12, 2020</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Change in quality of life measures from baseline to 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>24 months</time_frame>
    <description>Change in quality of life measures from baseline to 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 months</time_frame>
    <description>Change in HbA1c from baseline to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>24 months</time_frame>
    <description>Change in HbA1c from baseline to 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe hypoglycaemia</measure>
    <time_frame>12 months</time_frame>
    <description>Change in severe hypoglycaemia frequency from baseline to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe hypoglycaemia</measure>
    <time_frame>24 months</time_frame>
    <description>Change in severe hypoglycaemia frequency from baseline to 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in hypoglycaemia (&lt;54 mg/dL and &lt;70 mg/dL)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in time spent in hypoglycaemia (&lt;54 mg/dL and &lt;70 mg/dL) from baseline to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in hypoglycaemia (&lt;54 mg/dL and &lt;70 mg/dL)</measure>
    <time_frame>24 months</time_frame>
    <description>Change in time spent in hypoglycaemia (&lt;54 mg/dL and &lt;70 mg/dL) from baseline to 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisations because of hypoglycaemia and/or ketoacidosis</measure>
    <time_frame>12 months</time_frame>
    <description>Change in number of hospitalisations because of hypoglycaemia and/or ketoacidosis from baseline to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisations because of hypoglycaemia and/or ketoacidosis</measure>
    <time_frame>24 months</time_frame>
    <description>Change in number of hospitalisations because of hypoglycaemia and/or ketoacidosis from baseline to 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work and school absenteeism</measure>
    <time_frame>12 months</time_frame>
    <description>Change in work and school absenteeism from baseline to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work and school absenteeism</measure>
    <time_frame>24 months</time_frame>
    <description>Change in work and school absenteeism from baseline to 24 months</description>
  </secondary_outcome>
  <enrollment type="Actual">2331</enrollment>
  <condition>Diabetes</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients older than 4 years with diabetes using FGM after entering in the new diabetes
        reimbursement program in Belgium in UZ Leuven, OLVZ Aalst and UZ Antwerp.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  &gt;= 4 years

          -  Using flash glucose monitoring

        Exclusion Criteria:

          -  Doesn't want to sign the informed consent

          -  &lt; 4 years

          -  Not using flash glucose monitoring
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>prof dr Pieter Gillard</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

